iA Global Asset Management Inc. Buys 2,158 Shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX)

iA Global Asset Management Inc. grew its holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 18.6% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 13,763 shares of the company's stock after acquiring an additional 2,158 shares during the quarter. iA Global Asset Management Inc.'s holdings in IDEXX Laboratories were worth $5,690,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also recently bought and sold shares of the company. Empowered Funds LLC grew its holdings in shares of IDEXX Laboratories by 2.8% in the 3rd quarter. Empowered Funds LLC now owns 1,310 shares of the company's stock worth $662,000 after purchasing an additional 36 shares during the last quarter. Meeder Asset Management Inc. increased its holdings in IDEXX Laboratories by 616.0% in the third quarter. Meeder Asset Management Inc. now owns 179 shares of the company's stock valued at $90,000 after purchasing an additional 154 shares during the last quarter. Fifth Third Wealth Advisors LLC increased its stake in shares of IDEXX Laboratories by 11.0% in the 3rd quarter. Fifth Third Wealth Advisors LLC now owns 835 shares of the company's stock valued at $422,000 after acquiring an additional 83 shares during the last quarter. PNC Financial Services Group Inc. raised its holdings in IDEXX Laboratories by 0.5% in the third quarter. PNC Financial Services Group Inc. now owns 40,300 shares of the company's stock worth $20,360,000 after purchasing an additional 184 shares during the period. Finally, Prospera Private Wealth LLC acquired a new stake in IDEXX Laboratories during the 3rd quarter worth $157,000. 87.84% of the stock is owned by institutional investors.

Remove Ads

Insider Activity

In related news, Director M Anne Szostak sold 3,000 shares of the business's stock in a transaction dated Friday, February 7th. The stock was sold at an average price of $465.94, for a total transaction of $1,397,820.00. Following the transaction, the director now owns 3,061 shares in the company, valued at $1,426,242.34. The trade was a 49.50 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP George Fennell sold 9,986 shares of the firm's stock in a transaction dated Monday, February 10th. The stock was sold at an average price of $462.53, for a total transaction of $4,618,824.58. Following the completion of the sale, the executive vice president now directly owns 8,176 shares of the company's stock, valued at approximately $3,781,645.28. This represents a 54.98 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 2.11% of the company's stock.

Wall Street Analyst Weigh In

A number of equities analysts have issued reports on IDXX shares. Leerink Partners began coverage on IDEXX Laboratories in a report on Monday, December 2nd. They set an "outperform" rating and a $500.00 target price for the company. Leerink Partnrs raised IDEXX Laboratories to a "strong-buy" rating in a report on Monday, December 2nd. Piper Sandler boosted their price objective on IDEXX Laboratories from $435.00 to $510.00 and gave the stock a "neutral" rating in a report on Monday, February 10th. Bank of America boosted their price objective on shares of IDEXX Laboratories from $475.00 to $535.00 and gave the company a "neutral" rating in a report on Tuesday, February 4th. Finally, Barclays increased their target price on IDEXX Laboratories from $481.00 to $520.00 and gave the stock an "overweight" rating in a report on Tuesday, February 4th. Four research analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, IDEXX Laboratories currently has an average rating of "Moderate Buy" and a consensus price target of $533.75.

IDEXX Laboratories Stock Performance

NASDAQ:IDXX traded down $5.94 on Tuesday, reaching $417.66. 877,989 shares of the company's stock were exchanged, compared to its average volume of 552,266. The stock has a fifty day simple moving average of $437.38 and a 200-day simple moving average of $444.44. The firm has a market cap of $33.85 billion, a price-to-earnings ratio of 39.14, a P/E/G ratio of 3.41 and a beta of 1.39. IDEXX Laboratories, Inc. has a 52 week low of $398.50 and a 52 week high of $548.88. The company has a debt-to-equity ratio of 0.28, a current ratio of 1.31 and a quick ratio of 0.95.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.